# OnCo record paper-tpextreme-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tpextreme-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tpextreme-lancet-oncol-2021" ;
  schema:name "TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer"@en ;
  schema:description "Replacing fluorouracil with docetaxel in the cetuximab-platinum regimen for advanced head and neck cancer did not lengthen survival but was less toxic and much easier to give, so TPEx is an accepted alternative."@en ;
  schema:url <https://onco.cc/key-papers/paper-tpextreme-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30755-5>, <https://pubmed.ncbi.nlm.nih.gov/33684370/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30755-5> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Guigay J, Aupérin A, Fayette J, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:trials <https://onco.cc/trials/tpextreme/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .